HLS ASX: Pathology group Healius is restructuring management and cutting costs in its largest business, as UBS presses on with strategic review

  • 📰 FinancialReview
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 90%

المملكة العربية السعودية أخبار أخبار

المملكة العربية السعودية أحدث الأخبار,المملكة العربية السعودية عناوين

Australia’s No.2 pathology group is cutting costs in a restructure to try to turn around a profit slump, as UBS pushes on with a strategic review.

Two top executives in the group’s Queensland pathology business QML have departed in the restructure outlined in an internal email on March 27 from the boss of the Healius Pathology division, Jan Van Rooyen.

Healius, formerly known as Primary Health Care, replaced its chief executive, Maxine Jaquet, in early March after just 12 months in the job following a profit plunge and $2 billion in sharemarket value disappearing. A revival in the financial performance of the pathology division is crucial for Healius. Mr Van Rooyen was hired to run the division after having been the CEO of AMPATH in South Africa for almost 20 years, which he built into a national business after integrating several smaller operations.

 

شكرًا لك على تعليقك. سيتم نشر تعليقك بعد مراجعته.
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر:

 /  🏆 2. in SA

المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين